Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization
News Nov 18, 2017
The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint in the U.K., and further supports the growth of Quotient’s Translational Pharmaceutics® platform, following the acquisitions of SeaView Research and QS Pharma in February 2017.
Pharmaterials has a significant track record in supporting the development of small molecule drug products for oral and inhaled delivery. The company’s portfolio of services spans the characterization and optimization of drug substance physical forms, the development of preclinical and clinical formulations, through to clinical trial manufacturing and subsequent global drug product supply. The business was founded in 2000 and is located in a 48,000-square feet facility that houses 13 GMP manufacturing suites, with space for future expansion.
Mark Egerton, CEO, Quotient Sciences, said: “The acquisition of Pharmaterials strengthens Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing. The addition expands Quotient’s global CDMO services with added capacity and capabilities to better serve our clients’ needs.”
With over 700 employees, six operating sites across the U.S. and U.K. and a 30-year track record for quality services, Quotient is focused on delivering an innovative portfolio of services that are proven to shorten development timelines, reduce associated costs and accelerate the delivery of new medicines to patients globally.
Novel Lenses Enable X-ray Microscopy with Record ResolutionNews
Scientists have developed novel lenses that enable X-ray microscopy with record resolution in the nanometre regime. Using new materials, the research team has perfected the design of specialised X-ray optics and achieved a focus spot size with a diameter of less than ten nanometres.READ MORE
New Form of Matter DiscoveredNews
Scientists have proven the existence of an enigmatic new form of matter, which has perplexed scientists since it was first theorized almost 50 years ago - excitonium. This discovery was facilitated by using a novel technique they developed called momentum-resolved electron energy-loss spectroscopy.READ MORE
Uptake of Controlled Release Drug Delivery Technology Set to Increase?News
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages.READ MORE